BerGenBio Embarks on Promising Lung Cancer Trial
BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as bemcentinib. This research initiative is carried out in collaboration with the Mays Cancer Center at a prominent health science institution.
Research Insights and Objectives
The principal investigator of this trial, Dr. Josephine A. Taverna, a distinguished thoracic oncologist, has emphasized the synergy between AXL and the JAK-STAT3 pathway in promoting lung cancer progression. BerGenBio's CEO, Olav Hellebø, expressed optimism regarding the alignment of this study with the company’s mission—addressing significant gaps in treatment options for lung cancer patients, especially those battling mutations in the STK11 gene.
Bemcentinib and Pacritinib: A Powerful Combination
This unique trial will explore the effects of combining bemcentinib with pacritinib, a known JAK2 inhibitor that plays a crucial role in treating specific bone marrow disorders. Pacritinib is recognized for its ability to inhibit crucial growth factors, showcasing its therapeutic potential. This combination aims to target adenocarcinoma lung cancer, the prevalent form of lung cancer, which accounts for a substantial percentage of lung cancer cases.
Funding and Institutional Support
The trial is notably supported by funding from the National Cancer Institute, underlining its significance within the broader context of cancer research. The efforts to involve patients in this study reflect the increasing recognition of adenocarcinoma lung cancer’s impact on public health.
About the Trial
The trial, specifically designed as a Phase Ib/II study, will enroll a total of 44 patients. During the initial phase, varying doses of both bemcentinib and pacritinib will be systematically studied to evaluate their safety and tolerability. The secondary phase aims to assess the overall effectiveness of the selected doses, focusing on key outcomes such as patient response rate and progression-free survival.
Company Overview: BerGenBio
Founded with a vision to develop transformative therapies for serious diseases, BerGenBio ASA operates on the forefront of cancer research. Their flagship product, bemcentinib, represents a pioneering approach in targeting AXL, offering hope to patients with aggressive diseases, particularly lung cancer. The company is headquartered in Bergen, Norway, with a notable presence in Oxford, UK, and is publicly traded under the ticker BGBIO on the Oslo Stock Exchange.
Frequently Asked Questions
What is the focus of the trial announced by BerGenBio?
The trial focuses on exploring the efficacy of bemcentinib in combination with pacritinib for treating advanced adenocarcinoma lung cancer.
Who is leading the trial?
The trial is being led by Dr. Josephine A. Taverna, a reputable thoracic oncologist at the Mays Cancer Center.
What is bemcentinib?
Bemcentinib is a first-in-class selective AXL inhibitor aimed at treating serious diseases including lung cancer.
How many patients will be enrolled in the trial?
The trial anticipates enrolling a total of 44 patients to assess the safety and effectiveness of the treatment combination.
What kind of support is backing the trial?
The trial is funded by a grant from the National Cancer Institute, highlighting its importance in advancing cancer research.
